Bellicum Pharmaceuticals, Inc.
BLCMNASDAQHealthcare
$0.07
$-0.01(-6.68%)
Market Cap$778326
P/E Ratio—
52W High$1.31
52W Low$0.06
Bellicum Pharmaceuticals, Inc. (BLCM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BLCM · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 14, 2023EPS Actual
-$0.02
Revenue
$0.00B
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 14, 2023
After Market Close
🔥 9-Quarter EPS Beat Streak
BLCM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 14, 2023 | — | -$0.02 | — | $0.00B | — | — |
| ▲ Q3 FY2023 | Aug 10, 2023 | -$0.29 | -$0.24 | +17.2% | — | — | — |
| ▲ Q2 FY2023 | May 11, 2023 | -$0.34 | -$0.26 | +23.5% | $0.00B | — | — |
| ▲ Q1 FY2023 | Mar 24, 2023 | -$0.93 | -$0.27 | +71.0% | $0.00B | — | — |
| ▲ Q4 FY2022 | Nov 10, 2022 | -$0.64 | -$0.23 | +64.1% | $0.00B | — | — |
| ▲ Q3 FY2022 | Aug 11, 2022 | -$0.69 | -$0.13 | +81.2% | — | — | — |
| ▲ Q2 FY2022 | May 12, 2022 | -$0.67 | -$0.25 | +62.7% | — | — | — |
| ▲ Q1 FY2022 | Mar 24, 2022 | -$0.40 | -$0.27 | +32.5% | $0.00B | $0.00B | +100.0% |
Q4 FY2023
Nov 14, 2023
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2023
Aug 10, 2023Beat
EPS Actual
-$0.24
EPS Est.
-$0.29
EPS Surpr.
+17.2%
Revenue
—
Q2 FY2023
May 11, 2023Beat
EPS Actual
-$0.26
EPS Est.
-$0.34
EPS Surpr.
+23.5%
Revenue
$0.00B
Q1 FY2023
Mar 24, 2023Beat
EPS Actual
-$0.27
EPS Est.
-$0.93
EPS Surpr.
+71.0%
Revenue
$0.00B
Q4 FY2022
Nov 10, 2022Beat
EPS Actual
-$0.23
EPS Est.
-$0.64
EPS Surpr.
+64.1%
Revenue
$0.00B
Q3 FY2022
Aug 11, 2022Beat
EPS Actual
-$0.13
EPS Est.
-$0.69
EPS Surpr.
+81.2%
Revenue
—
Q2 FY2022
May 12, 2022Beat
EPS Actual
-$0.25
EPS Est.
-$0.67
EPS Surpr.
+62.7%
Revenue
—
Q1 FY2022
Mar 24, 2022Beat
EPS Actual
-$0.27
EPS Est.
-$0.40
EPS Surpr.
+32.5%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 0 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 0 |
| Q1 FY2024 | $1.57 | $1.57 | $1.57 | 0 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 0 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 0 |
| Q2 FY2023 | $-0.29 | $-0.29 | $-0.29 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 15 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 8 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 10 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 8 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 11 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 17 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 14, 2023 | — | $0.10 | $0.10 | +0.29% |
| ▲ Q3 FY2023 | Aug 10, 2023 | +17.2% | $0.48 | $0.48 | +0.64% |
| ▲ Q2 FY2023 | May 11, 2023 | +23.5% | $0.82 | $0.80 | -2.56% |
| ▲ Q1 FY2023 | Mar 24, 2023 | +71.0% | $0.30 | $0.28 | -3.66% |
| ▲ Q4 FY2022 | Nov 10, 2022 | +64.1% | $1.12 | $1.13 | +0.89% |
| ▲ Q3 FY2022 | Aug 11, 2022 | +81.2% | $1.37 | $1.42 | +3.76% |
| ▲ Q2 FY2022 | May 12, 2022 | +62.7% | $1.37 | $1.43 | +4.38% |
| ▲ Q1 FY2022 | Mar 24, 2022 | +32.5% | $1.98 | $2.01 | +1.52% |
Q4 FY2023+0.29%
Report Date
Nov 14, 2023
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q3 FY2023+0.64%
Report Date
Aug 10, 2023
EPS Beat/Miss
+17.2%
Price Before
$0.48
Price After
$0.48
Q2 FY2023-2.56%
Report Date
May 11, 2023
EPS Beat/Miss
+23.5%
Price Before
$0.82
Price After
$0.80
Q1 FY2023-3.66%
Report Date
Mar 24, 2023
EPS Beat/Miss
+71.0%
Price Before
$0.30
Price After
$0.28
Q4 FY2022+0.89%
Report Date
Nov 10, 2022
EPS Beat/Miss
+64.1%
Price Before
$1.12
Price After
$1.13
Q3 FY2022+3.76%
Report Date
Aug 11, 2022
EPS Beat/Miss
+81.2%
Price Before
$1.37
Price After
$1.42
Q2 FY2022+4.38%
Report Date
May 12, 2022
EPS Beat/Miss
+62.7%
Price Before
$1.37
Price After
$1.43
Q1 FY2022+1.52%
Report Date
Mar 24, 2022
EPS Beat/Miss
+32.5%
Price Before
$1.98
Price After
$2.01
Avg Beat Reaction+0.71%
Beat Rate7 / 8 quarters
Largest Move+4.38% (Q2 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BLCM ends December
Bellicum Pharmaceuticals, Inc. (BLCM) most recently reported earnings on November 14, 2023 for Q4 FY2023, posting EPS of $-0.02 (in line with the analyst consensus of —). BLCM has beaten EPS estimates for 9 consecutive quarters. The next BLCM earnings date is expected around September 1, 2026.
Each quarter, investors track BLCM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BLCM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BLCM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BLCM earnings · 4 questionsBellicum Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. BLCM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BLCM historically reports after market close (AMC).
BLCM earnings datewhen is BLCM earningsBLCM next earnings datewhen does BLCM report earningsBLCM earnings calendar
▸ Source: FMP · Bellicum Pharmaceuticals, Inc. SEC filings · US GAAP · Bellicum Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026